4AB trade ideas
ABBV - Potential Reversal coming 2019ABBV has been losing some value in their stock since January 2018.. Some trends we can see on the chart, are a couple fibonacci patterns, farthest on left is since the stock started, and closer on the right side is the latest dip on. The retrace has hit the long term 50% Fibonacci level and bounced off. Volume has been low, however.
We draw trend lines and see a falling wedge pattern developing. This will usually call for a reversal, and we can start to use a couple other indicators as well. We can use Fibonacci retrace levels to assume when downward trend may hit major resistance. We can draw in our Moving Averages for future glimpses, and also take a look at RSI for selling volume, as the stock price falls.
This is one I will be keeping my eye on, as we beak into 2019. I believe ABBV has good earnings potential, has a good dividend, and overall is a strong company. Being a Daily chart, we will be looking further down the road for this to play out. Smaller patterns will develop and play out before this may happen. Look for breakout of current trends to make any moves.
I marked this chart as SHORT (short term only). I find it confusing when making a LONG call on longer term charts, while knowing the stock price is still expected to dip short term.
Another stock in trouble. Nice short entryHey As you can see its testing Key Resistance. Descending triangle. Negative divergence, Negative Cash Flow...
AbbVie Announces Positive Results from CLL14ABBV: AbbVie
2018-10-31 16:14:00
AbbVie Announces Positive Results from CLL14, a Phase 3 Trial Evaluating a Venetoclax Combination as First-Line Therapy with a Fixed Duration of Treatment in Patients with Chronic Lymphocytic Leukemia
ABBVIE - Technical AnalysisDear Traders,
ABBVIE looks to be on the edge for a breakout, the MACD shows a Bullish Hidden Divergence which backs-up my LONG position.
Any thoughts ?
About Abbvie:
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the discovery, development, manufacture and sale of a line of proprietary pharmaceutical products. It is focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on January 1, 2013 and is headquartered in North Chicago, IL.
AbbVie Announces Patient-Reported Outcomes Data from Three PivotABBV: AbbVie
2018-09-13 06:20:00
AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis
Defense is favored atleast right now #ABBVAscending triangle breakout will be bullish for ABBV. Things going for ABBV have been lot of insider buying. If it breaks out, will add more
ABBV Looking to break through Ichi CloudABBV has broken and retested the downward trend line. Looks like it has a good shot to push through cloud resistance.
ABBV Detected possible FDA approval!!!ABBV: abbvie inc
2018-07-24 08:30:26
Detected possible FDA approval
$ABBV - I'm a fan Little extra, but put in both ABCD 61.8% fib corrections just to show definitive correlation for each re-trace. Definitely think that touch of the 50% is needed for an upward swing, but long term I can definitely see a 161% (200% on MA fib) move back up towards $115. Still pretty choppy price action, so my best bet would be to wait until @ or crossing over that $102 (blue WMA) area. Great setup tho
ABBV ABBV is a very high quality stock. It never missed an earnings estimate. Accordingly, my homebrew stock valuation system gives it pretty high scores quality-wise.
"val2_k": 5,
"val2_q": 8,
"qual2_k": 60,
"qual2_q": 51,
"qual3_k": 59
TA wise, It does seem like ABBV is finishing wave 2 and starts making into 3 of (5) of III. Lots of long term potential for this stock.
Though it seems like wave 2 ended at exactly 50% of wave 1, historically, this stocks has shown that wave 2 can retrace upto 76.4% of wave 1. In short, ABBV can find short term low anywhere from 93 to 98 before mooning.
Long term target for wave (5) of III is estimated at $145. A nice 45% potential.
ABBV - when having all your eggs in one basket works outAbbVie's bread winner is Humira - this drug accounts for the majority of their revenue. However, they did forecast that by 2020, revenue from Humira will be $21B - which is about 75% of their 2017 revenue of $28.22B.
Since AbbVie depends so heavily on their flagship, their stock is fairly volatile, giving this play more of a risk. Consider well-hedged positions (like married puts), or at least ITM leap calls.
ABBV continues to fill gap - short-term PT $112NYSE:ABBV PRICE TARGET - $112 in the short-term. We remain long, the fundamental picture looks outstanding!
ABBV gapping upWe have been long ABBV for a while! The stock is gapping up today after the company announced a cash tender offer for up to $7.5B of its common stock at prices between $99 and 114 per share.
